Germany· DE-A57-f72b89be59de865e

Gilurytmal

A ajmaline product containing ajmaline, registered in Germany by Carinopharm Gmbh. The same ATC class is registered in 3 of our 19 countries.

ATC C01BA05

Checked against EMA Article 57 (European Union) on

Informational only — not a medical device.

SOURCE REGISTER · DEEMA Article 57 (European Union)normalisedGilurytmalATCC01BA05REGISTER NO.DE-A57-f72b89be59de86…PACKS LISTED0CHECKEDSeptember 30, 2026

Where it is registered

Ajmaline is registered in 3 of 19 countries.

Countries holding a registration under ATC C01BA05 (ajmaline), each read from that country’s own register.

  • This record: Germany, from EMA Article 57 (European Union)
  • 1 of them publish a price we can compare per daily dose

Ajmaline · ATC C01BA05

3 / 19 countries

  • Finlandprice
  • Germany
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

EMA Article 57 (European Union)
Active substance
Ajmaline
Manufacturer
Carinopharm Gmbh
Country
Germany (DE)
ATC code
C01BA05
ATC class
Ajmaline
Defined daily dose
0.3 g, O
Reimbursed
Not published by this register
Source register
EMA Article 57 (European Union)
Last checked
September 30, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Ajmaline in 1 other country

What each register calls a product with the same active substance — salts and hydrates count as the same.

All ajmaline products

Authorised across Europe · EMA

The same active substance is authorised in 1 EEA country. Names it is sold under:

  • Austria · Gilurytmal

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of EMA Article 57 (European Union). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/096406e3-7d14-465f-b50e-048d1acb0197
GET /v1/drugs/096406e3-7d14-465f-b50e-048d1acb0197?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "pzn": null,
  "route": "Intravenous Use",
  "source": "ema_art57_de",
  "ma_number": null,
  "substance": "Ajmaline",
  "atc_from_source": null,
  "authorisation_country": "Germany"
}

See everything about ajmaline.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.